Chembio Stock Financials

CEMI
 Stock
  

USD 0.63  0.04  5.97%   

Chembio Diagnostics Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 52.03 Million. The current Invested Capital Average is estimated to increase to about 56.4 M, while Net Income Per Employee is projected to decrease to (103.3 K).
  
Refresh
With this module, you can analyze Chembio financials for your investing period. You should be able to track the changes in Chembio Diagnostics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Chembio Most Recent Estimates

Diluted Eps
-1.43
EPS Estimate Current Year
-0.9
EPS Estimate Current Quarter
-0.21
Earnings Share
-1.43

Revenues

41.89 Million

Share
Understanding current and past Chembio Diagnostics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Chembio Diagnostics' financial statements are interrelated, with each one affecting the others. For example, an increase in Chembio Diagnostics' assets may result in an increase in income on the income statement.
The fundamental analysis of Chembio Diagnostics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Chembio Diagnostics includes many different criteria found on its balance sheet. For example, investors should never minimize Chembio Diagnostics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Chembio Diagnostics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Chembio Diagnostics.

Chembio Diagnostics Cash

Chance Of Financial Distress
Over 93
Chembio Diagnostics has more than 93 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Chembio Diagnostics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Chembio Diagnostics' official financial statements usually reflect Chembio Diagnostics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Chembio Diagnostics. For example, before you start analyzing numbers published by Chembio accountants, it's critical to develop an understanding of what Chembio Diagnostics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Chembio Diagnostics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Chembio Diagnostics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Chembio Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Chembio Diagnostics. Please utilize our Beneish M Score to check the likelihood of Chembio Diagnostics' management to manipulate its earnings.

Chembio Diagnostics Company Summary

Chembio Diagnostics competes with Agilent Technologies, Allena Pharmaceuticals, Intel Corp, Coca Cola, and Home Depot. Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or diagnose diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York. Chembio Diagnostics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 337 people.
Specialization
Healthcare, Diagnostics & Research
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001092662
CUSIP163572100
RegionNorth America
LocationNew York; U.S.A
Business Address555 Wireless Boulevard,
SectorHealthcare
IndustryDiagnostics & Research
BenchmarkDOW
Websitewww.chembio.com
Phone631 924 2065
CurrencyUSD - US Dollar
You should never invest in Chembio Diagnostics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Chembio Stock, because this is throwing your money away. Analyzing the key information contained in Chembio Diagnostics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Chembio Diagnostics Key Financial Ratios

Generally speaking, Chembio Diagnostics' financial ratios allow both analysts and investors to convert raw data from Chembio Diagnostics' financial statements into concise, actionable information that can be used to evaluate the performance of Chembio Diagnostics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Chembio Diagnostics reports annually and quarterly.

Chembio Diagnostics Key Balance Sheet Accounts

201720182019202020212022 (projected)
Inventories4.42 M7.85 M9.6 M12.52 M12.92 M13.94 M
Receivables2.09 M7.37 M3.66 M3.38 M11.44 M12.34 M
Accounts Payable1.49 M3.62 M3.14 M5.73 M7.75 M8.36 M
Total Assets16.62 M40.91 M55.73 M64.89 M73.25 M58.3 M
Current Assets10.85 M28.45 M32.22 M39.74 M55.23 M59.59 M
Assets Non Current5.76 M12.46 M23.51 M25.15 M18.02 M15.89 M
Cash and Equivalents3.79 M12.52 M18.27 M23.07 M28.77 M31.04 M
Deferred Revenue50 K422.9 K125 K1.61 M1.85 M1.99 M
Shareholders Equity13.08 M33.33 M24.04 M27.78 M34.26 M30.33 M
Inventory4.42 M7.85 M9.6 M12.52 M12.92 M10.27 M
Total Liabilities3.54 M7.58 M31.69 M37.12 M38.99 M42.07 M
Current Liabilities3.1 M6.52 M6.44 M12.35 M15.28 M16.49 M

Chembio Diagnostics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Chembio Diagnostics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses12.92 M21.43 M22.39 M23.87 M34.5 M37.22 M
Consolidated Income(6.37 M)(7.87 M)(13.68 M)(25.52 M)(33.9 M)(34.8 M)
Cost of Revenue12.92 M22.6 M22.39 M23.87 M34.5 M28.6 M
Gross Profit11.09 M11.98 M12.07 M8.6 M13.32 M13.29 M
Net Income(6.37 M)(7.87 M)(13.68 M)(25.52 M)(33.9 M)(34.8 M)
Operating Expenses17.58 M19.96 M25.4 M31.73 M44.38 M47.88 M
Operating Income(6.48 M)(7.98 M)(13.33 M)(23.14 M)(31.05 M)(31.87 M)
Revenues24.02 M34.58 M34.46 M32.47 M47.82 M41.89 M
Income Tax Expense(88.31 K)(67.52 K)(500.29 K)(456.79 K)(62.05 K)(66.95 K)

Chembio Diagnostics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Chembio Diagnostics. It measures of how well Chembio is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Chembio Diagnostics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Chembio had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Chembio Diagnostics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(1.03 M)(1.47 M)(3.5 M)(3.96 M)(1.82 M)(1.97 M)
Depreciation Amortization and Accretion1.28 M902.5 K1.92 M2.7 M2.93 M3.16 M
Net Cash Flow or Change in Cash and Cash Equivalents(6.76 M)8.73 M5.75 M4.79 M5.71 M6.16 M
Issuance Purchase of Equity Shares34.8 K27.55 M32.49 K28.44 M38.9 M41.97 M
Net Cash Flow from Financing134.28 K27.48 M18.49 M27.76 M38.69 M41.74 M
Net Cash Flow from Investing(1.88 M)(6.96 M)(3.75 M)(4.17 M)(1.86 M)(2 M)
Net Cash Flow from Operations(5.03 M)(11.78 M)(9.06 M)(18.89 M)(30.89 M)(31.7 M)
Share Based Compensation384.9 K632.8 K1.66 M1.22 M2.43 M2.62 M

Chembio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Chembio Diagnostics's current stock value. Our valuation model uses many indicators to compare Chembio Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chembio Diagnostics competition to find correlations between indicators driving Chembio Diagnostics's intrinsic value. More Info.
Chembio Diagnostics is number one stock in working capital category among related companies. It is number one stock in shares owned by institutions category among related companies . The ratio of Working Capital to Shares Owned by Institutions for Chembio Diagnostics is about  809,562 . Chembio Diagnostics Working Capital is most likely to increase significantly in the upcoming years. The last year's value of Working Capital was reported at 39.95 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Chembio Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Chembio Diagnostics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Chembio Diagnostics' earnings, one of the primary drivers of an investment's value.

Chembio Diagnostics Systematic Risk

Chembio Diagnostics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Chembio Diagnostics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Chembio Diagnostics correlated with the market. If Beta is less than 0 Chembio Diagnostics generally moves in the opposite direction as compared to the market. If Chembio Diagnostics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Chembio Diagnostics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Chembio Diagnostics is generally in the same direction as the market. If Beta > 1 Chembio Diagnostics moves generally in the same direction as, but more than the movement of the benchmark.
.

About Chembio Diagnostics Financials

What exactly are Chembio Diagnostics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Chembio Diagnostics' income statement, its balance sheet, and the statement of cash flows. Potential Chembio Diagnostics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Chembio Diagnostics investors may use each financial statement separately, they are all related. The changes in Chembio Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Chembio Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Chembio Diagnostics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Chembio grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Chembio Diagnostics June 30, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Chembio Diagnostics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Chembio Diagnostics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Chembio Diagnostics based on widely used predictive technical indicators. In general, we focus on analyzing Chembio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Chembio Diagnostics's daily price indicators and compare them against related drivers.
Information Ratio(0.023747)
Maximum Drawdown34.03
Value At Risk(8.45)
Potential Upside11.94
Continue to Trending Equities. Note that the Chembio Diagnostics information on this page should be used as a complementary analysis to other Chembio Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Chembio Stock analysis

When running Chembio Diagnostics price analysis, check to measure Chembio Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chembio Diagnostics is operating at the current time. Most of Chembio Diagnostics' value examination focuses on studying past and present price action to predict the probability of Chembio Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chembio Diagnostics' price. Additionally, you may evaluate how the addition of Chembio Diagnostics to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Chembio Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chembio Diagnostics. If investors know Chembio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chembio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
19.6 M
Quarterly Revenue Growth YOY
1.16
Return On Assets
-0.26
Return On Equity
-1.53
The market value of Chembio Diagnostics is measured differently than its book value, which is the value of Chembio that is recorded on the company's balance sheet. Investors also form their own opinion of Chembio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Chembio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chembio Diagnostics' market value can be influenced by many factors that don't directly affect Chembio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chembio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chembio Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chembio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.